Nuveen’s Q1 2026 13F Shows Mild Accumulation Amid a $12.6B AUM Dip

Nuveen’s March 31 2026 filing reveals a portfolio that is rebalancing rather than expanding. Total assets under management fell to $369.27 billion, a $12.63 billion (‑3.3%) drop from the prior quarter, even though the year‑to‑date figure remains 12% above the 2025‑Q4 level. The decline is driven primarily by price‑driven de‑valuation of large‑cap technology positions rather than wholesale selling, as the flow analysis shows a flow ratio of 1.48×, placing the fund in the mild‑accumulation band (1.1×‑1.5×). The conviction ratio of 0.61 exceeds the 0.60 threshold, indicating that Nuveen is still adding to existing stakes more often than trimming them.

The most pronounced shift is the $6.96 billion reduction in Microsoft, achieved by shedding 4.04 million shares, a decline of 8.4% in share count. Amazon and Broadcom also saw sizable cuts, with Amazon down $1.71 billion (‑3.1% shares) and Broadcom down $1.49 billion (‑1.3% shares). These moves reflect a strategic tilt away from the high‑valuation tech segment that has been under pressure from rising component costs and AI‑driven memory shortages, a backdrop highlighted by IDC’s report of a 4.1% year‑over‑year fall in global smartphone shipments.

Conversely, the fund’s biggest absolute increase came from Costco Wholesale, where Nuveen added 901,338 shares, a 41.5% boost worth $1.19 billion. Energy exposure also rose, with Chevron up $575.8 million and Exxon Mobil up $1.16 billion, underscoring a tilt toward more defensive, cash‑generating sectors. The Nushares ETF position expanded by 37.36 million shares (+36.8%), adding $901.3 million, suggesting a modest foray into diversified equity exposure.

New positions further illustrate the fund’s diversification drive. The largest fresh stake is AstraZeneca PLC, entered with 6.78 million shares valued at $1.31 billion, followed by Sunbelt Rentals at $155.6 million and Piper Sandler at $53.4 million. While some of these names also appear among exits—AstraZeneca saw a partial sale of 542,568 shares worth $49.9 million—the net effect is an overall increase in exposure to pharmaceuticals and specialty finance.

The portfolio’s concentration remains moderate. The top ten holdings account for 31.8% of AUM, well below the 50% hedge‑fund threshold, confirming Nuveen’s broadly diversified asset‑manager profile. NVIDIA, Apple, Microsoft, Amazon, Broadcom, and Alphabet together represent the core of the equity exposure, but the recent trimming of Microsoft and Amazon reduces the weight of the tech cluster.

From a flow perspective, the fund recorded 74 new positions and 100 exits, with 1,757 increased and 1,137 decreased holdings. The net increase in share count (1,757 – 1,137 = 620) aligns with the mild‑accumulation classification. The flow ratio of 1.48× indicates that the dollar value of new and increased positions exceeds that of closed and decreased positions by 48%, a clear sign that Nuveen is still building exposure, albeit cautiously.

Overall, Nuveen’s Q1 2026 filing paints a picture of a manager navigating a volatile macro environment by trimming high‑beta tech while reinforcing consumer staples, energy, and select pharma bets. The modest AUM contraction reflects market‑driven valuation shifts rather than aggressive divestiture, and the fund’s conviction metrics suggest confidence in the remaining large‑cap positions. Investors should watch whether the mild accumulation trend persists into the next quarter, especially as component‑cost pressures and AI‑related supply constraints continue to shape sector dynamics.